As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... grew ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Analyst Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report) and keeping the price target ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.